Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 23;2015(6):CD010896.
doi: 10.1002/14651858.CD010896.pub2.

Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia

Hilary A Archer  1 , Nadja Smailagic, Christeena John, Robin B Holmes, Yemisi Takwoingi, Elizabeth J Coulthard, Sarah Cullum
Affiliations

Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia

Hilary A Archer et al. Cochrane Database Syst Rev. .

Abstract

Background: In the UK, dementia affects 5% of the population aged over 65 years and 25% of those over 85 years. Frontotemporal dementia (FTD) represents one subtype and is thought to account for up to 16% of all degenerative dementias. Although the core of the diagnostic process in dementia rests firmly on clinical and cognitive assessments, a wide range of investigations are available to aid diagnosis.Regional cerebral blood flow (rCBF) single-photon emission computed tomography (SPECT) is an established clinical tool that uses an intravenously injected radiolabelled tracer to map blood flow in the brain. In FTD the characteristic pattern seen is hypoperfusion of the frontal and anterior temporal lobes. This pattern of blood flow is different to patterns seen in other subtypes of dementia and so can be used to differentiate FTD.It has been proposed that a diagnosis of FTD, (particularly early stage), should be made not only on the basis of clinical criteria but using a combination of other diagnostic findings, including rCBF SPECT. However, more extensive testing comes at a financial cost, and with a potential risk to patient safety and comfort.

Objectives: To determine the diagnostic accuracy of rCBF SPECT for diagnosing FTD in populations with suspected dementia in secondary/tertiary healthcare settings and in the differential diagnosis of FTD from other dementia subtypes.

Search methods: Our search strategy used two concepts: (a) the index test and (b) the condition of interest. We searched citation databases, including MEDLINE (Ovid SP), EMBASE (Ovid SP), BIOSIS (Ovid SP), Web of Science Core Collection (ISI Web of Science), PsycINFO (Ovid SP), CINAHL (EBSCOhost) and LILACS (Bireme), using structured search strategies appropriate for each database. In addition we searched specialised sources of diagnostic test accuracy studies and reviews including: MEDION (Universities of Maastricht and Leuven), DARE (Database of Abstracts of Reviews of Effects) and HTA (Health Technology Assessment) database.We requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies and used the related articles feature in PubMed to search for additional studies. We tracked key studies in citation databases such as Science Citation Index and Scopus to ascertain any further relevant studies. We identified 'grey' literature, mainly in the form of conference abstracts, through the Web of Science Core Collection, including Conference Proceedings Citation Index and Embase. The most recent search for this review was run on the 1 June 2013.Following title and abstract screening of the search results, full-text papers were obtained for each potentially eligible study. These papers were then independently evaluated for inclusion or exclusion.

Selection criteria: We included both case-control and cohort (delayed verification of diagnosis) studies. Where studies used a case-control design we included all participants who had a clinical diagnosis of FTD or other dementia subtype using standard clinical diagnostic criteria. For cohort studies, we included studies where all participants with suspected dementia were administered rCBF SPECT at baseline. We excluded studies of participants from selected populations (e.g. post-stroke) and studies of participants with a secondary cause of cognitive impairment.

Data collection and analysis: Two review authors extracted information on study characteristics and data for the assessment of methodological quality and the investigation of heterogeneity. We assessed the methodological quality of each study using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool. We produced a narrative summary describing numbers of studies that were found to have high/low/unclear risk of bias as well as concerns regarding applicability. To produce 2 x 2 tables, we dichotomised the rCBF SPECT results (scan positive or negative for FTD) and cross-tabulated them against the results for the reference standard. These tables were then used to calculate the sensitivity and specificity of the index test. Meta-analysis was not performed due to the considerable between-study variation in clinical and methodological characteristics.

Main results: Eleven studies (1117 participants) met our inclusion criteria. These consisted of six case-control studies, two retrospective cohort studies and three prospective cohort studies. Three studies used single-headed camera SPECT while the remaining eight used multiple-headed camera SPECT. Study design and methods varied widely. Overall, participant selection was not well described and the studies were judged as having either high or unclear risk of bias. Often the threshold used to define a positive SPECT result was not predefined and the results were reported with knowledge of the reference standard. Concerns regarding applicability of the studies to the review question were generally low across all three domains (participant selection, index test and reference standard).Sensitivities and specificities for differentiating FTD from non-FTD ranged from 0.73 to 1.00 and from 0.80 to 1.00, respectively, for the three multiple-headed camera studies. Sensitivities were lower for the two single-headed camera studies; one reported a sensitivity and specificity of 0.40 (95% confidence interval (CI) 0.05 to 0.85) and 0.95 (95% CI 0.90 to 0.98), respectively, and the other a sensitivity and specificity of 0.36 (95% CI 0.24 to 0.50) and 0.92 (95% CI 0.88 to 0.95), respectively.Eight of the 11 studies which used SPECT to differentiate FTD from Alzheimer's disease used multiple-headed camera SPECT. Of these studies, five used a case-control design and reported sensitivities of between 0.52 and 1.00, and specificities of between 0.41 and 0.86. The remaining three studies used a cohort design and reported sensitivities of between 0.73 and 1.00, and specificities of between 0.94 and 1.00. The three studies that used single-headed camera SPECT reported sensitivities of between 0.40 and 0.80, and specificities of between 0.61 and 0.97.

Authors' conclusions: At present, we would not recommend the routine use of rCBF SPECT in clinical practice because there is insufficient evidence from the available literature to support this.Further research into the use of rCBF SPECT for differentiating FTD from other dementias is required. In particular, protocols should be standardised, study populations should be well described, the threshold for 'abnormal' scans predefined and clear details given on how scans are analysed. More prospective cohort studies that verify the presence or absence of FTD during a period of follow up should be undertaken.

PubMed Disclaimer

Conflict of interest statement

Hilary A Archer ‐ none known Nadja Smailagic‐ none known Christeena John‐ none known Robin B Holmes‐ none known Yemisi Takwoingi‐ none known Elizabeth J Coulthard‐ none known Sarah Cullum‐ none known

Figures

1
1
Flow diagram.
2
2
'Risk of bias' and applicability concerns summary: review authors' judgements about each domain for each included study
3
3
'Risk of bias' and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies
4
4
Forest plot of single‐headed and multiple‐headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD) from non‐FTD. The studies are ordered according to study design, reference standard (RS) and sensitivity. TP: true positive; FP: false positive; FN: false negative; TN: true negative; CI: confidence interval.
5
5
Summary ROC plot of single‐headed and multiple‐headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD) from non‐FTD. Each symbol represents the sensitivity and specificity of a study. Different colours are used to indicate the two camera types and different symbols are used to indicate study design.
6
6
Forest plot of single‐headed and multiple‐headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD) from Alzheimer's disease dementia (AD). The studies are ordered according to study design, reference standard (RS) and sensitivity. TP: true positive; FP: false positive; FN: false negative; TN: true negative; CI: confidence interval.
7
7
Summary ROC plot of single‐headed and multiple‐headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD) from Alzheimer's disease dementia (AD). Each symbol represents the sensitivity and specificity of a study. Different colours are used to indicate the two camera types and different symbols are used to indicate study design.
1
1. Test
FTD versus non‐FTD: Single‐headed camera rCBF SPECT.
2
2. Test
FTD versus non‐FTD: Multiple‐headed camera rCBF SPECT.
3
3. Test
FTD versus AD: Single‐headed camera rCBF SPECT.
4
4. Test
FTD versus AD: Multiple‐headed camera rCBF SPECT.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010896

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Boutoleau‐Bretonniere 2012 {published data only}
    1. Boutoleau‐Bretonniere C, Lebouviera T, Delaroche O, Lamy E, Evrard C, Charriau T, et al. Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia. Journal of Alzheimer’s Disease 2012;28(2):323–36. - PubMed
Horn 2007 {published data only}
    1. Horn JF, Habert MO, Giron A, Fertil B. Alzheimer's disease and frontotemporal dementia differential automatic diagnosis based on SPECT images. Biomedical Imaging: From Nano to Macro, 2007. ISBI 2007. 4th IEEE International Symposium on Biomedical Imaging; 2007 April 12‐15; Arlington, VA, USA. IEEE, 2007:1336‐9.
    1. Horn JF, Habert MO, Kas A, Malek Z, Maksud P, Lacomblez L, et al. Differential automatic diagnosis between Alzheimer’s disease and frontotemporal dementia based on perfusion SPECT images. Artificial Intelligence in Medicine 2009;47(2):147‐58. - PubMed
Launes 1991 {published data only}
    1. Launes J, Sulkava R, Erkinjuntti T, Nikkinen P, Lindroth L, Liewendahl K, et al. 99Tcm‐HMPAO SPECT in suspected dementia. Nuclear Medicine Communications 1991;12(9):757‐65. - PubMed
Lipton 2004 {published data only}
    1. Lipton AM, Benavidesa R, Hynan LS, Bonte FJ, Harris TS, White CL, et al. Lateralization on neuroimaging does not differentiate frontotemporal lobar degeneration from Alzheimer’s disease. Dementis and Geriatriatric Cognitive Disorders 2004;17(4):324‐7. - PubMed
McNeill 2007 {published data only}
    1. McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, et al. Accuracy of single‐photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 2007;78(4):350–5. - PMC - PubMed
Nagao 2004 {published data only}
    1. Nagao M, Sugawara Y, Ikeda M, Fukuhara R, Hokoishi K, Murase K, et al. Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging 2004;31(2):162‐8. - PubMed
Pickut 1997 {published data only}
    1. Pickut BA, Saerens J, Marien P, Borggreve F, Goeman J, Vandevivere J, et al. Discriminative use of SPECT in frontal lobe‐type dementia versus (senile) dementia of the Alzheimer's type. Journal of Nuclear Medicine 1997;38(6):929‐34. - PubMed
Read 1995 {published data only}
    1. Read SL, Miller BL, Mena I, Kim R, Itabashi H, Darby A. SPECT in dementia: clinical and pathological correlation. Journal of the American Geriatrics Society 1995;43(11):1243‐7. - PubMed
Rollin‐Sillaire 2012 {published data only}
    1. Rollin‐Silliare A, Bombois S, Deramecourt V, Steinert‐Emptaz A, Salleron J, Morvan J, et al. Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. Journal of Alzheimer's Disease 2012;30(4):833‐45. - PubMed
Talbot 1998 {published data only}
    1. Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc‐HMPAO SPECT in the investigation of dementia?. Journal of Neurology, Neurosurgery, and Psychiatry 1998;63(3):306–13. - PMC - PubMed
Valotassiou 2012 {published data only}
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Kapsalaki E, et al. Perfusion SPECT studies with mapping of Brodmann areas in differentiating Alzheimer's disease from frontotemporal degeneration syndromes. Nuclear Medicine Communications 2012;33(12):1267‐76. - PubMed
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzvara C, Tsougos J, Kapsalaki E, et al. Brain perfusion SPECT with Brodmann areas mapping in the differential diagnosis of Alzheimer's disease from behavioural variant of frontotemporal lobar degeneration. European Journal of Nuclear Medicine and Molecular Imaging 2011;38(Suppl 2):S260‐441.

References to studies excluded from this review

Barnes 2000 {published data only}
    1. Barnes A, Lusman D, Pattersona J, Brown D, Wyper D. The use of statistical pParametric mapping (SPM96) as a decision aid in the differential diagnosis of dementia using 99mTc‐HMPAO SPECT. Behavioural Neurology 2000;12(1‐2):77‐86. - PubMed
Barquero 1996 {published data only}
    1. Barquero MS, Dominguez M, Encinas M, Barabash A, Cabranes JA, Varela de Seijas E. Primary progressive aphasia: diagnosis and evolution using brain SPECT. Fifth International Conference on Alzheimer's Disease and Related Disorders. Osaka, Japan July 1996. Neurobiology of Aging. 1996; Vol. 17(4), issue 4 Suppl:S92.
Boeve 2012 {published data only}
    1. Boeve BF, Boylan KB, Graff‐Radford NR, DeJesus‐Hernandez M, Knopman DS, Pedraza O, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012;135:765‐83. - PMC - PubMed
Bonte 1994 {published data only}
    1. Bonte F, Tintner R, Weiner M, Bigio E, White C. Histopathological validation of brain blood flow SPECT in the differential diagnosis of the dementias. 39th annual Meeting of the Southwestern Chapter of the Society of Nuclear Medicine. Albuquerque, New Mexico, USA 1994. Clinical Nuclear Medicine. 1994; Vol. 19(3):260.
Bonte 2004 {published data only}
    1. Bonte FJ, Harris TS, Roney CA, Hynan LS. Differential diagnosis between Alzheimer’s and frontotemporal disease by the posterior cingulate sign. Journal of Nuclear Medicine 2004;45(5):771‐4. - PubMed
Borghesani 2010 {published data only}
    1. Borghesani PR, DeMers SM, Manchanda V, Pruthi S, Lewis DH, Borson S. Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. Journal of the American Geriatrics Society 2010;58(8):1453‐8. - PMC - PubMed
Borroni 2010 {published data only}
    1. Borroni B, Agosti C, Premi E, Cerini C, Cosseddu M, Paghera B, et al. The FTLD‐modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in frontotemporal lobar degeneration: evidence from a brain SPECT study. European Journal of Neurology 2010;17(5):703‐7. - PubMed
Borroni 2012 {published data only}
    1. Borronia B, Grassi M, Premi E, Alberici A, Cosseddu M, Cancelli V, et al. Is long‐term prognosis of frontotemporal lobar degeneration predictable by neuroimaging? Evidence from a single‐subject functional brain study. Journal of Alzheimer's Disease 2012;29(4):883‐90. - PubMed
Buchpiguel 1996 {published data only}
    1. Buchpiguel CA, Mathias SC, Itaya LY, Barros NG, Portela LA, Freitas JM, et al. Brain SPECT in dementia. A clinical‐scintigraphic correlation. Arquivos de Neuro‐psiquiatria 1996;54(3):375‐83. - PubMed
Didic 1998 {published data only}
    1. Didic M, Giusiano B, Laforte C, Ceccaldi M, Poncet M. Identification of clinical subtypes of fronto‐temporal dementia and cerebral blood flow on SPECT: preliminary results. Alzheimer's Reports 1998;1(3):179‐85.
Frisoni 1992 {published data only}
    1. Frisoni GB, Bianchetti A, Pizzolato G, Ferlin G, L Battistin L, Trabucchi M. Functional imaging (99mTc‐HMPAO SPECT) and clinical findings in the differentiation of Alzheimer's disease and dementia of frontal type. Third International Conference on Alzheimer's disease and related disorders. Abano Terme, Italy, July 1992. Neurobiol Aging. 1992; Vol. 13 Suppl 1:S16.
Frisoni 1995 {published data only}
    1. Frisoni GB, Pizzolato G, Geroldi C, Rossato A, Bianchetti A, Trabucchi M. Dementia of the frontal type: neuropsychological and [99Tc]‐HM‐PAO SPET features. Journal of Geriatric Psychiatry and Neurology 1995;8(1):42‐8. - PubMed
Grace 2001 {published data only}
    1. Grace J, Zawacki TM, Ott BR, Boyle P, Noto R. Behavioral, neuropsychological, and SPECT correlates of frontal lobe functioning in dementia. Brain and Cognition. 2001; Vol. 47, issue 1‐2:279‐82.
Hannequin 2001 {published data only}
    1. Hannequin D, Lefevre MHS, Bakchine S, Kotzki PO, Vera P. Primary progressive aphasia: a bilateral temporal lobe involvment. Neurology. 2001; Vol. 56, issue Suppl 3:A189.
Hogh 2004 {published data only}
    1. Hogh P, Teller AS, Hasselbalch SG, Waldemar G. Clinical progression of MCI or questionable dementia and predictive value of HMPAO‐SPECT: Follow‐up study of 115 patients from a multidisciplinary memory clinic based in neurology.. 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, USA July 2004. Neurobiology of Aging. 2004; Vol. 25 Suppl 2:S272.
Honda 2002 {published data only}
    1. Honda N, Machida K, Hosono M, Matsumoto T, Matsuda H, Oshima M, et al. Interobserver variation in diagnosis of dementia by brain perfusion SPECT. Radiation Medicine 2002;20(6):281‐9. - PubMed
Joseph 2006 {published data only}
    1. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006;129(Pt 6):1385‐98. - PMC - PubMed
Julin 1995 {published data only}
    1. Julin P, Wahlund LO, Basun H, Persson A, Måre K, Rudberg U. Clinical diagnosis of frontal lobe dementia and Alzheimer’s disease: relation to cerebral perfusion, brain atrophy and electroencephalography. Dementia 1995;6(3):142‐7. - PubMed
Kaneko 2004 {published data only}
    1. Kaneko K, Kuwabara Y, Sasaki M, Ogomori K, Ichimiya A, Koga H, et al. Posterior cingulate hypoperfusion in Alzheimer’s disease, senile dementia of Alzheimer type, and other dementias evaluated by three‐dimensional stereotactic surface projections using Tc‐99m HMPAO SPECT. Clinical Nuclear Medicine 2004;29(6):362‐6. - PubMed
Le Ber 2006 {published data only}
    1. Ber I, Guedj E, Gabelle A, Verpillat P, Volteau M, Thomas‐Anterion C, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006;129(Pt 11):3051‐65. - PubMed
Lojkowska 2002 {published data only}
    1. Lojkowska W, Ryglewicza D, Jedrzejczak T, Sienkiewicz‐Jarosz H, Minc S, Jakubowska T, et al. SPECT as a diagnostic test in the investigation of dementia. Journal of the Neurological Sciences 2002;203‐204:215‐9. - PubMed
Mendez 2007 {published data only}
    1. Mendez MF, Shapira JS, McMurtray A, Licht E, Miller BL. Accuracy of the clinical evaluation for frontotemporal dementia. Archives of Neurology 2007;64(6):830‐5. - PubMed
Miller 1997 {published data only}
    1. Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, et al. A study of the Lund‐Manchester research criteria for frontotemporal dementia: clinical and single‐photon emission CT correlations. Neurology 1997;48(4):937‐42. - PubMed
Miller 1999 {published data only}
    1. Miller BL, Gearhart R. Neuroimaging in the diagnosis of frontotemporal dementia. Dementia and Geriatric Cognitive Disorders 1999;10(Suppl 1):71‐4. - PubMed
Papma 2013 {published data only}
    1. Papma JM, Seelaar H, Koning I, Hasan D, Reijs A, Valkema R, et al. Episodic memory impairment in frontal dementia; A 99mTc‐HMPAO SPECT study. Current Alzheimer Research 2013;10(3):332‐9. - PubMed
Sjogren 2000 {published data only}
    1. Sjögren M, Gustafson L, Wikkelsö C, Wallin A. Frontotemporal dementia can be distinguished from Alzheimer’s disease and subcortical white matter dementia by an anterior‐to‐posterior rCBF‐SPET ratio. Dementia and Geriatric Cognitive Disorders 2000;11(5):275‐85. - PubMed
Talbot 1995 {published data only}
    1. Talbot PR, Snowden JS, Lloyd JJ, Neary D, Testa HJ. The contribution of single photon emission tomography to the clinical differentiation of degenerative cortical brain disorders. Journal of Neurology 1995;242(9):579‐86. - PubMed
Valotassiou 2009 {published data only}
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Karageorgiou C, Tsougos I, Tzavara C, et al. Evaluation of brain perfusion in specific Brodmann areas in frontotemporal dementia and Alzheimer disease using automated 3‐D voxel based analysis. Journal of Instrumentation 2009;4:doi:10.1088/1748‐0221/4/05/P05020.
Valotassiou 2011 {published data only}
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos J, Psimadas D, et al. Evaluation of perfusion differences in semantic dementia and Alzheimer's disease using Tc‐99m‐HMPAO SPECT with automated Brodmann areas mapping. European Journal of Nuclear Medicine and Molecular Imaging 2011;38(Suppl 2):S323.
Valotassiou 2012a {published data only}
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos J, Psimadas D, et al. Alzheimer's disease and progressive non‐fluent aphasia: evaluation of perfusion differences using 99mTc‐HMPAO SPECT and Brodmann areas mapping.. 25th Annual Congress of the European Association of Nuclear Medicine (EANM) Milan Italy Oct 2012. European Journal of Nuclear Medicine and Molecular Imaging. 2012; Vol. 39 (Suppl 2):S547.
Valotassiou 2012b {published data only}
    1. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos J, Psimadas D, et al. Patterns of perfusion deficit in semantic dementia and progressive non‐fluent aphasia: a Tc‐99m‐HMPAO SPECT study with Brodmann areas mapping. 25th Annual Congress of the European Association of Nuclear Medicine (EANM) Milan Italyn Oct 2012. European Journal of Nuclear Medicine and Molecular Imaging. 2012; Vol. 39(Suppl 2):S547.
Waragai 2008 {published data only}
    1. Waragai M, Mizumura S, Yamada T, Matsuda H. Differentiation of early‐stage Alzheimer’s disease from other types of dementia using brain perfusion single photon emission computed tomography with easy Z‐score imaging system analysis. Dementia and Geriatric Cognitive Disorders 2008;26(6):547‐55. - PubMed

Additional references

Alzheimer's Disease International 2010
    1. Alzheimer's Disease International. World Alzheimer report 2010. The global economic impact of dementia. www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf 2010 (accessed 14 May 2015).
Alzheimer's Society 2007
    1. Alzheimer's Society. Dementia UK 2007. www.alzheimers.org.uk/site/scripts/download_info.php?fileID=2 2007 (accessed 14 May 2015).
American Psychiatric Association 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. http://dsm.psychiatryonline.org//book.aspx?bookid=556 2013 (accessed 14 May 2015).
Ball 1997
    1. Ball MG, Braak H, Coleman P, Dickson D, Duyckaerts C, Gambetti P, et al. Consensus recommedations for the postmortem diagnosis of Alzheimer's disease: The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. neurobiology of Aging 1997;18:S1‐S2. - PubMed
Brun 1994
    1. Brun A, England B, Gustafson L, et al. Clinical and neuropathological criteria for frontotempora;l dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57:416‐8. - PMC - PubMed
Cairns 2007
    1. Cairns NG, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Consortium for Frontotemporal Lobar Degeneration.Neuropathologic diagnostic and nosologic criteria for frontotempolar lobar degeneration: Consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathologica 2007;114:5‐22. - PMC - PubMed
Catafau 2001
    1. Catafau AM. Brain SPECT in clinical practice. Part I: perfusion. Journal of Nuclear Medicine 2001;42(2):259‐71. - PubMed
Chui 1992
    1. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42(3 Pt 1):473‐80. - PubMed
Chung 2000
    1. Chung HW, Huang YH. Fractal analysis of nuclear medicine images for the diagnosis of pulmonary emphysema:interpretations, implications, and limitations. American Journal of Roentgenology 2000;174:1055‐9. - PubMed
Davis 2013
    1. Davis DHJ, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010460] - DOI - PMC - PubMed
Ferri 2005
    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112‐7. - PMC - PubMed
Geslani 2005
    1. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005;19(5‐6):383‐9. - PubMed
Gibb 1989
    1. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989;112:1171‐92. - PubMed
Glanville 2010
    1. Glanville JM, Cikalo M, Crawford F, Dozier M, Lowson P. Handsearching for reports of diagnostic test accuracy studies: adding to the evidence base. Oral presentation at the Joint Cochrane and Campbell Colloquium; 2010 Oct 18‐22; Keystone, Colorado, USA [abstract]. CMR Metodologia Cochrane ID:CMR 15328. 2010; Vol. Suppl:48.
Hendrie 1988
    1. Hendrie HC, Hall KS, Brittain HM, Austrom MG, Farlow M, Parker J, et al. The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. Journal of the American Geriatrics Society 1988;36(5):402‐8. - PubMed
Hokoishi 2001
    1. Hokoishi K, Ikeda M, Maki N, et al. Frontotemporal lobar degeneration: a study in Japan. Dementia and Geriatric Cognitive Disorders 2001;12:393‐9. - PubMed
Hughes 2001
    1. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497‐99. - PubMed
Juni 2009
    1. Juni JE, Waxman AD, Devous MD Sr, Tikofsky RS, Ichise M, Heertum RL, et al. Procedure guideline for brain perfusion SPECT using (99m)Tc radiopharmaceuticals 3.0. Journal of Nuclear Medicine Technology 2009;37(3):191‐5. - PubMed
Kapucu 2009
    1. Kapucu OL, Nobili F, Varrone A, Booij J, Vander Borght T, Någren K, et al. EANM procedure guideline for brain perfusion SPECT using 99mTc‐labelled radiopharmaceuticals, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2009;36(12):2093‐102. - PubMed
Knopman 2001
    1. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey‐Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence‐based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143‐53. - PubMed
Litvan 1996
    1. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome): Report of the NINDS‐SPSP international workshop. Neurology 1996;47:1‐9. - PubMed
Lund and Manchester Groups 1994
    1. Clinical and neuropathological criteria forfrontotemporal dementia. The Lund and Manchester Groups. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416‐8. - PMC - PubMed
Mackenzie 2010
    1. Mackenzie IRA, Neumann M, Bigio EH, Cairns NG, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica 2010;119(1):1‐4. - PMC - PubMed
Mackenzie 2011
    1. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD‐TDP pathology. Acta Neuropathologica 2011;122(1):111‐3. - PMC - PubMed
Mahoney 2012
    1. Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135(Pt 3):736‐50. - PMC - PubMed
Mann 1993
    1. Mann DMA, South PW. The topographic distributaion of brain atrophy in frontal lobe dementia. Acta Neuropathologica 1993;85:334‐40. - PubMed
Matthews 2009
    1. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable‐risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Medicine 2009;6(11):e1000180. - PMC - PubMed
McKeith 2005
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O' Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863‐72. - PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939‐44. - PubMed
McKhann 2001
    1. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Archives of Neurology 2001;58(11):1803‐9. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263‐9. - PMC - PubMed
Mirra 1991
    1. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479‐86. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264‐9. - PubMed
MRC CFAS 2001
    1. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late‐onset dementia in a multicentre, community‐based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357(9251):169‐75. - PubMed
Nagao 2002
    1. Nagao M, Murase K. Measurement of heterogeneous distribution on Technegas SPECT images by three‐dimensional fractal analysis. Annals of Nuclear medicine 2002;16(6):369‐76. - PubMed
NAO 2007
    1. National Audit Office. Improving services and support for people with dementia. http://www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf 4 July 2007 (accessed 14 May 2015).
Neary 1986
    1. Neary D, Snowden JS, Bowen DM, et al. Neuropsychological syndromes in presenile dementia due to cerebral atrophy. Journal of Neurology, neurosurgery, and Psychiatry 1986;49:163‐74. - PMC - PubMed
Neary 1998
    1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6):1546‐54. - PubMed
NICE 2006
    1. National Institute for Health and Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. Clinical guidelines CG42.. http://guidance.nice.org.uk/CG42/NICEGuidance/pdf/English November 2006 (accessed 14 May 2015).
Okello 2009
    1. Okello A, Koivunen J, Edison P, Archer HA, Turkhemer FE, Nagren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C‐PIB PET study. Neurology 2009;73(10):754‐60. - PMC - PubMed
Rascovsky 2007
    1. Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions.. Alzheimer Disease and Associated Disorders 2007;21(4):S14‐8. - PubMed
Rascovsky 2011
    1. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456‐77. - PMC - PubMed
Ratnavalli 2002
    1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58(11):1615‐21. - PubMed
Review Manager 2013 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manage (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology 1993;43(2):250‐60. - PubMed
Savva 2009
    1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. The New England Journal of Medicine 2009;360(22):2302‐9. - PubMed
Seelaar 2011
    1. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82(5):476‐86. - PubMed
Shi 2005
    1. Shi J, Shaw CL, Richardson AMT, et al. Hystopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathologica 2005;110:501‐12. - PubMed
Steinling 1988
    1. Steinling M, Mazingue A, Kassiotis P, Gaudet Y, Fialdes P, Duhamel A, et al. MmPaO TC as an indicator of local cerebral blood flow: Quantfied study compared to xenon 133 inhalation method. Annals of Radiology 1988;31:229‐38. - PubMed
Steinling 1989
    1. Steinling M, Leys D, Amagassi F, Soetart G, Vernes R. Can Alzheimer and multi infarct dementia be differentiated using 99m‐Tc‐HMPAO tomograms. In: Circulation cerebrale et viellissement, G Geraud‐A Bes, Eds.John Libbey Eurotext 1989:291‐4.
Visser 2006
    1. Visser PJ, Kester A, Jolles J, Verhey F. Ten‐year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67(7):1201‐7. - PubMed
Whiting 2011
    1. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. Journal of Clinical Epidemiology 2011;64(6):602‐7. - PubMed
WHO 2010
    1. World Health Organization. International Classification of Diseases and Related Health Problems 10th revision (ICD‐10). http://www.who.int/entity/classifications/icd/ICD10Volume2_en_2010.pdf 2010 (accessed 14 May 2015).

Publication types

MeSH terms

LinkOut - more resources